Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Clin Cancer Res. 2015 Oct 12;22(5):1211–1221. doi: 10.1158/1078-0432.CCR-15-0663

Figure 6. ATRA combined with Sorafenib has enhanced apoptosis induction ability in primary AML cells and MOML13 cells.

Figure 6

The combined effect of ATRA and Sorafenib on apoptosis induction in primary cells isolated from 4 cases of AML patients was examined after treatment with 1 μM ATRA and 2.5 μM Sorafenib for 2 days (A). The apoptotic cells were detected with Annexin V-FITC assay using flow cytometry. ** P <0.01 compared with cells treated with either ATRA or Sorafenib alone. The combined effects of ATRA and Sorafenib on Mcl-1 protein and its potential regulators in primary AML cells isolated from #2 patient were examined using specific antibodies with Western blot (B). The combined effect of ATRA and Sorafenib on apoptosis induction (C) and protein levels (D) in MOLM13 cells was examined after treatment with 1 μM ATRA and 15 nM Sorafenib for 2 days. Mice survival after treatment with Sorafenib and ATRA, as described in Material and Methods, is shown in Kaplan-Meyer survival plot (E) and the average survival times of each group and increase of life span over control was calculated (F). Five mice were used in each group.